Yuanhua Lu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yuanhua Lu has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Chenchen Tang
Biobank, Jilin Cancer Hospital, Changchun 130012, China
1 shared publication Chunjiao Wu
Department of Medical Oncology Jilin Cancer Hospital Changchun China
1 shared publicationFrank Wu
TransThera Sciences (Nanjing). Inc. Fl 3, Bld 9, Phase 2 Accelerator Biotech and Pharmaceutical Valley, Jiangbei New Area Nanjing Jiangsu China
1 shared publicationHui Li
Biobank Jilin Cancer Hospital Changchun China
1 shared publicationPeiyan Zhao
Medical Oncology Translational Research Lab Jilin Cancer Hospital Changchun China
1 shared publicationPeng Peng
TransThera Sciences (Nanjing). Inc. Fl 3, Bld 9, Phase 2 Accelerator Biotech and Pharmaceutical Valley, Jiangbei New Area Nanjing Jiangsu China
1 shared publication
Latest Publications
- Open Access
- 16 January 2025
- Published by Wiley in Cancer Science
- Vol. 116 (4) , 951-965
Multiple Kinase Small Molecule Inhibitor Tinengotinib (TT‐00420) Alone or With Chemotherapy Inhibit the Growth of SCLC
There is an urgent need to develop new targeted treatment agents for small cell lung cancer (SCLC). Tinengotinib (TT‐00420) is a novel, multi‐targeted, and spectrally selective small‐molecule kinase inhibitor that has shown significant inhibitory effects on certain solid tumors in preclinical studies. However, its role and mechanism of action in SCLC remain unclear. In this study, we demonstrated that tinengotinib effectively inhibited SCLC cell proliferation, especially highly expressing NeuroD1 (SCLC‐N), in the SCLC cell line‐derived xenograft (CDX) model and the malignant pleural effusion cell model of patients with SCLC. When combined with etoposide/cisplatin, it synergistically inhibited SCLC growth. Tinengotinib regulates proliferation, apoptosis, migration, cell cycle and angiogenesis in SCLC cells. Mechanistic studies revealed that c‐Myc expression may be a key factor influencing the effect of tinengotinib in SCLC‐N. This study provides reliable preclinical data and a new direction for tinengotinib as a promising therapy for SCLC, either alone or in combination with chemotherapy.
- 16 January 2025
- Published by Wiley in Cancer Science
- Vol. 116 (4) , 951-965
Open AccessMultiple Kinase Small Molecule Inhibitor Tinengotinib (TT‐00420) Alone or With Chemotherapy Inhibit the Growth of SCLC
There is an urgent need to develop new targeted treatment agents for small cell lung cancer (SCLC). Tinengotinib (TT‐00420) is a novel, multi‐targeted, and spectrally selective small‐molecule kinase inhibitor that has shown significant inhibitory effects on certain solid tumors in preclinical studies. However, its role and mechanism of action in SCLC remain unclear. In this study, we demonstrated that tinengotinib effectively inhibited SCLC cell proliferation, especially highly expressing NeuroD1 (SCLC‐N), in the SCLC cell line‐derived xenograft (CDX) model and the malignant pleural effusion cell model of patients with SCLC. When combined with etoposide/cisplatin, it synergistically inhibited SCLC growth. Tinengotinib regulates proliferation, apoptosis, migration, cell cycle and angiogenesis in SCLC cells. Mechanistic studies revealed that c‐Myc expression may be a key factor influencing the effect of tinengotinib in SCLC‐N. This study provides reliable preclinical data and a new direction for tinengotinib as a promising therapy for SCLC, either alone or in combination with chemotherapy.